A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

oxo Oncology Inc0 个研究点目标入组 250 人开始时间: 2021年9月1日最近更新: 2021年9月7日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 250

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Patients are eligible to be included in the study only if all of the following criteria apply:
•1. Age 18 and older per local regulations at time of enrollment.
•Type of Patient and Disease Characteristics
•2. Confirmed diagnosis by redacted local laboratory report of CLL/SLL as defined by iwCLL 2018 criteria including the following:
•a) B cells coexpressing the surface antigen CD5 together with at least one B-cell antigen (CD19, CD20, CD23) and either ? or ? light-chain restricted.
•b) = 5 × 109 B lymphocytes/L (5000/µL) in the peripheral blood. For SLL patients, history of = 5 × 109 B lymphocytes/L (5000/µL) in the peripheral blood is allowed.
•c) Prolymphocytes may comprise = 55% of blood lymphocytes.
•3. A requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy such that at least 1 of the following should be met:
•a) Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (such as hemoglobin < 10 g/dL) and/or thrombocytopenia (such as platelets = 100 × 109/L).
•b) Massive (i.e., spleen edge = 6 cm below the left costal margin) or progressive or symptomatic splenomegaly (> 13 cm).
•c) Massive nodes (i.e., = 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
•d) Progressive lymphocytosis with an increase of > 50% over a 2-month period, or lymphocyte doubling time < 6 months. Factors contributing to lymphocytosis other than CLL/SLL (e.g., infections, steroid administration) should be excluded.
•e) Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids.
•f) Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, spine).
•g) Disease-related symptoms (also known as B-symptoms) as defined by any of the following:
•i) Unintentional weight loss = 10% within the previous 6 months.
•ii) Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance scale 2 or worse; cannot work or unable to perform usual activities).
•iii) Fevers = 100.5°F or 38.0°C for 2 or more weeks without evidence of infection.
•iv) Night sweats for = 1 month without evidence of infection.
•4. Known 17p deletion status.
•5. Previously treated with a covalent BTK inhibitor, investigational or approved, and either alone or in combination with other agents. Patients may have received an unlimited number of lines of prior therapy.
•6. Eastern Cooperative Oncology Group (ECOG) 0-2.
•7. Must have adequate organ function, as defined below. These values must be met during the screening period as well as pre-dose on Cycle 1 Day 1 (C1D1).
•8. Patients are required the have had the following washout periods prior to planned C1D1:
•a) Targeted agents or cytotoxic chemotherapy: 5 half-lives or 2 weeks, whichever is shorter
•b) Therapeutic monoclonal antibodies: 4 weeks
•c) Palliative limited field radiation: 7 days
•d) Broad field radiation (= 30% of bone marrow or whole brain radiotherapy): 28 days
•9. Prior treatment related AEs must have recovered to Grade = 1 or pretreatment baseline with the exception of alopecia.
•Contraception
•10. Willingness of men and women of reproductive potential to observe conventional and highly effective or acceptable birth control methods for the duration of treatment and for 6 months following the last dose of study treatment or 12 months after the last dose of rituximab.
•Informed Consent
•11. Willing and capable of giving signed informed consent which includes compliance with the requirements and re

排除标准

•Patients are excluded from the study if any of the following criteria apply:
•Medical Conditions
•1. Known or suspected Richter’s transformation to diffuse large B cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin lymphoma at any time preceding enrollment.
•2. Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.
•3. History of Grade =2 arrhythmia on prior covalent BTK inhibitor.
•4. Patients who experienced a major bleeding event on a prior BTK inhibitor.
•NOTE: major bleeding is defined as bleeding having one or more of the following features: life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2 g/dL; or bleeding in a critical area or organ (e.g. retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)
•5. Active second malignancy. Patients with treated second malignancy who are in remission with life expectancy > 2 years and with documented sponsor approval are eligible.
•Examples include:
•a) Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease.
•b) Adequately treated cervical carcinoma in situ without current evidence of disease.
•c) Localized (e.g., lymph node negative) breast cancer treated with curative intent with no evidence of active disease present for more than 3 years and receiving adjuvant hormonal therapy.
•d) Localized prostate cancer undergoing active surveillance.
•e) History of treated and cured Hodgkin's disease or NHL within 5 years from diagnosis.
•6. Major surgery, within 4 weeks of planned start of study treatment.
•7. History of or ongoing drug-induced pneumonitis.
•8. Ongoing drug-induced liver injury, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis and cirrhosis of the liver.
•9. History of allogeneic or autologous SCT or CAR-T therapy within the past 60 days
•10. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) not on a stable regimen and dose for at least 4 weeks prior to study enrollment
•11. Significant Cardiovascular disease defined as:
•a) Unstable angina or acute coronary syndrome within the past 2 months,
•b) History of myocardial infection within 3 months prior to planned start of LOXO-305,
•c) Documented LVEF by any method of = 40% in the 12 months prior to planned start of LOXO-305,
•d) = Grade 3 NYHA functional classification system of heart failure, uncontrolled or symptomatic arrhythmias
•12. Prolongation of the QT interval corrected (QTc) for heart rate using Fredericia’s Formula (QTcF) > 470 msec on at least 2 of 3 consecutive ECGs, and mean QTcF > 470 msec on all 3 ECGs, during Screening.
•a) QTcF is calculated using Fredericia’s Formula (QTcF = QT/(RR^0.33)
•b) Correction of suspected drug-induced QTcF prolongation or prolongation due to electrolyte abnormalities can be attempted at the investigator’s discretion, and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation or electrolyte supplementation.
•c) Correction of QTc for underlying bundle branch block (BBB) permissible.
•13. Hepatitis B or hepatitis C testing indicating active/ongoing infection based on screening labs as defined as:
•a) Hepatitis B virus (HBV): Patients with positive hep

研究者

发起方

oxo Oncology Inc

相似试验

进行中（未招募）

1 期

A Phase 3 Study Comparing LOXO-305 to Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus RituximabChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-004554-30-IEoxo Oncology Inc250

进行中（未招募）

1 期

EUCTR2020-004554-30-HRoxo Oncology Inc250

进行中（未招募）

1 期

EUCTR2020-004554-30-CZoxo Oncology Inc250

招募中

1 期

A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL 321)Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104

CTIS2023-507697-40-00oxo Oncology Inc.238

招募中

3 期

A Phase 3 Study of LOXO-305 in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

JPRN-jRCT2021210031Shahda , MD Safi10